EGFR-IN-174

EGFR-IN-174 is a potent EGFR inhibitor (IC50 = 0.17 μM) and also displays VEGFR-2 inhibition (IC50 = 0.2007 μM) . EGFR-IN-174 exhibits potent anticancer effects with low cytotoxicity to normal cells. EGFR-IN-174 induces G2/M and Pre-G1 phase arrest and significantly triggers apoptosis. EGFR-IN-174 can be used in cancer research, such as colorectal carcinoma, hepatocellular carcinoma, and breast cancer[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; EGFR; VEGFR

Related Pathways

Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

S=C(N/N=C(C1=CC=C(S(=O)(N2CCC(C)CC2)=O)C=C1)\C)SC

Molecular Formula

C16H23N3O2S3

Molecular Weight

385.57

References & Citations

[1]Al-Ziyadi SH, et al. Novel Sulfonamide Derivatives as Anticancer Agents, VEGFR‑2 Inhibitors, and Apoptosis Triggers: Design, Synthesis, and Computational Studies. ACS Omega. 2025 Aug 25;10 (35) :39772-39790.